Cargando…

Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?

BACKGROUND AND AIMS: Irritable bowel syndrome (IBS) is a chronic relapsing disorder characterized by abdominal pain-discomfort and altered bowel habits. The IBS-diarrhoea predominant subtype (IBS-D) is defined as >25% of bowel movements representing type 6 or 7 of the Bristol Stool Form Scale. Ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakraborty, Dwaipayan Sarathi, Hazra, Avijit, Sil, Amrita, Pain, Shantasil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857390/ https://www.ncbi.nlm.nih.gov/pubmed/31742138 http://dx.doi.org/10.4103/jfmpc.jfmpc_522_19

Ejemplares similares

The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review
por: Daniluk, Jaroslaw, et al.
Publicado: (2022)

Acupuncture for Diarrhoea-Predominant Irritable Bowel Syndrome: A Network Meta-Analysis
por: Zhu, Lingping, et al.
Publicado: (2018)

Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website
por: Everitt, Hazel, et al.
Publicado: (2013)

Review article: an analysis of safety profiles of treatments for diarrhoea‐predominant irritable bowel syndrome
por: Lacy, Brian E.
Publicado: (2018)

Somatization in patients with predominant diarrhoea irritable bowel syndrome: the role of the intestinal barrier function and integrity
por: Prospero, Laura, et al.
Publicado: (2021)

Involvement of mucosal flora and enterochromaffin cells of the caecum and descending colon in diarrhoea-predominant irritable bowel syndrome
por: Yang, Jingze, et al.
Publicado: (2021)

A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial
por: El-Haggar, Sahar M, et al.
Publicado: (2022)

Comparative evaluation of efficacy and safety of drotaverine versus mebeverine in irritable bowel syndrome: A randomized double-blind controlled study
por: Rai, Ramesh R., et al.
Publicado: (2021)

A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial [Retraction]
Publicado: (2022)

Randomized Clinical Trial: The Clinical Effects of Herb-Partitioned Moxibustion in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome
por: Ma, Yu-xia, et al.
Publicado: (2013)

Randomised clinical trial: exploratory phase 2 study of ONO‐2952 in diarrhoea‐predominant irritable bowel syndrome
por: Whitehead, W. E., et al.
Publicado: (2016)

Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial)
por: Everitt, Hazel A, et al.
Publicado: (2010)

Mebeverine for Pediatric Functional Abdominal Pain: A Randomized, Placebo-Controlled Trial
por: Pourmoghaddas, Zahra, et al.
Publicado: (2014)

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
por: Fodor, Anthony A., et al.
Publicado: (2018)

Effects of herb-partitioned moxibustion for diarrhoea-predominant irritable bowel syndrome: A protocol for systematic review and meta-analysis
por: Wang, Fen, et al.
Publicado: (2020)

Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation
por: Hamatani, Tatsuto, et al.
Publicado: (2020)

Association between Brachyspira and irritable bowel syndrome with diarrhoea
por: Jabbar, Karolina S, et al.
Publicado: (2021)

Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers
por: Krogius-Kurikka, Lotta, et al.
Publicado: (2009)

Constipation-Predominant Irritable Bowel Syndrome Associated to Hyperprolactinemia
por: Seretis, C., et al.
Publicado: (2011)

Targeted therapies for diarrhea-predominant irritable bowel syndrome
por: Olden, Kevin W
Publicado: (2012)

Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
por: Lacy, Brian E
Publicado: (2016)

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Özdener, Ayşe Elif, et al.
Publicado: (2017)

Comparison of Quality of Life and Psychiatric Symptoms Between Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Those With Constipation-Predominant Irritable Bowel Syndrome
por: BOUSABA, J., et al.
Publicado: (2023)

Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial
por: Leighton, Matthew P, et al.
Publicado: (2013)

A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
por: Garsed, Klara, et al.
Publicado: (2014)

Pilot study: a randomised, double blind, placebo controlled trial of pancrealipase for the treatment of postprandial irritable bowel syndrome-diarrhoea
por: Money, Mary E, et al.
Publicado: (2011)

pH-Sensitive Mebeverine Microspheres for Colon Delivery
por: Dandagi, P. M., et al.
Publicado: (2009)

Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update
por: Andrews, Christopher N, et al.
Publicado: (2019)

Efficacy and Safety of Acupoint Catgut Embedding for Diarrhea-Predominant Irritable Bowel Syndrome and Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
por: Wu, Jing, et al.
Publicado: (2020)

The Effect of Phloroglucinol in Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial
por: Shin, Seung Yong, et al.
Publicado: (2020)

Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients
por: Andrae, David A, et al.
Publicado: (2013)

High prevalence of primary bile acid diarrhoea in patients with functional diarrhoea and irritable bowel syndrome-diarrhoea, based on Rome III and Rome IV criteria
por: Shiha, Mohamed G., et al.
Publicado: (2020)

Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways
por: Hou, Qiuke, et al.
Publicado: (2019)

Impact of symptom severity in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D): results from two separate surveys of HCPs and patients with IBS-D
por: Emmanuel, Anton, et al.
Publicado: (2020)

Drug-Loaded Silver Nanoparticles—A Tool for Delivery of a Mebeverine Precursor in Inflammatory Bowel Diseases Treatment
por: Todorova, Mina, et al.
Publicado: (2023)

Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Sobolewska-Włodarczyk, Aleksandra, et al.
Publicado: (2016)

Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2018)

Characterization of kynurenine pathway in patients with diarrhea-predominant irritable bowel syndrome
por: Li, Pingping, et al.
Publicado: (2020)

Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation
por: Mourey, Florian, et al.
Publicado: (2022)

A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome
por: Khalilian, Alireza, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mg33me1cahocaqjbgd9ut55qu0